Signal transduction and targeted therapy
Osimertinib inhibits the MYLK4-mediated phosphorylation of CDKAL1 to suppress stemness and chemoresistance in rhabdomyosarcoma.
Takuto Itano, Rongsheng Huang, Toshifumi Ozaki, Eiji Nakata, Atsushi Fujimura
Published: 202610.1038/s41392-025-02548-6
No abstract available for this study.